While different types of progressive familial intrahepatic cholestasis (PFIC) vary in their genetic cause and clinical profile, new medications like Bylvay (odevixibat) and Livmarli (maralixibat) have shown promise across several PFIC types, including rare ones, in children. That’s according to a review study, titled “New hope in treating progressive familial intrahepatic cholestasis in children,” which […] The post New medications show promise for children with rare liver disease app...
